David F. Hoffmeister
David F. Hoffmeister's purchase track record
David F. Hoffmeister has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/30/2024 | STEP | $997K | +22.8% | +51.1% | +15.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
GKOS Joins Big Stocks Rising on Wednesday; 10‑Year Gains Highlight. GKOS was among the large stocks that gained on Wednesday, adding to its recent upward momentum. A Benzinga piece noted that a $1,000 investment in GKOS 10 years ago would be worth a substantial amount today, underscoring the company's long‑term growth. These stories highlight both the current price action and the company's historical performance.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
ICU Medical Highlighted in Zacks Industry Outlook. ICU Medical was featured in recent Zacks industry outlooks alongside Neogen and Trulieve, with analysts noting that certain medical product stocks are positioned to benefit from broader industry tailwinds. These mentions suggest continued analyst attention to the company's role in the medical device sector. The stock currently trades with a high trailing P/E of 135.9, while the average analyst target price stands at $193.38.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Celanese Sets Q3 Earnings Call for November 3, 2026. Celanese has announced it will hold its third-quarter earnings conference call on November 3, 2026. The company is also mentioned in a new industry report on thermo compression forming, which highlights its role in advanced manufacturing. With the stock trading near its 52-week low, upcoming earnings results may provide clarity on the company's performance.
Transaction History
| STEP | ▲ Buy | Grant | 5,616 | $285K | 9/8/2026 | View on chart |
| GKOS | ▲ Buy | Grant | 1,878 | $0 | 5/28/2026 | View on chart |
| GKOS | ▲ Buy | Option Exercise | 15,000 | $370K | 5/26/2026 | View on chart |
| ICUI | ▲ Buy | Option Exercise | 1,254 | $0 | 5/13/2026 | View on chart |
| GKOS | ▲ Buy | Grant | 753 | $0 | 1/2/2026 | View on chart |
| STEP | ▲ Buy | Grant | 3,691 | — | 9/9/2025 | View on chart |
| GKOS | ▲ Buy | Option Exercise | 25,000 | $800K | 6/11/2025 | View on chart |
| GKOS | ▲ Buy | Grant | 2,108 | $0 | 5/29/2025 | View on chart |
| ICUI | ▲ Buy | Option Exercise | 1,723 | $0 | 5/13/2025 | View on chart |
| CE | ▲ Buy | Grant | 3,376 | $0 | 5/9/2025 | View on chart |
| GKOS | ▲ Buy | Grant | 557 | $0 | 1/2/2025 | View on chart |
| STEP | ▲ Buy | Grant | 3,926 | — | 9/10/2024 | View on chart |
| STEP | ▲ Buy | Open Market | 22,500 | $997K | 5/30/2024 | View on chart |
| GKOS | ▲ Buy | Grant | 1,716 | $0 | 5/30/2024 | View on chart |
| ICUI | ▲ Buy | Option Exercise | 948 | $0 | 5/15/2024 | View on chart |
| CE | ▲ Buy | Grant | 1,114 | $175K | 5/15/2024 | View on chart |
| GKOS | ▲ Buy | Option Exercise | 10,000 | $73K | 4/10/2024 | View on chart |
| GKOS | ▲ Buy | Grant | 1,082 | $0 | 1/2/2024 | View on chart |
| STEP | ▲ Buy | Grant | 6,317 | — | 9/13/2023 | View on chart |
| GKOS | ▲ Buy | Grant | 3,230 | $0 | 6/1/2023 | View on chart |
| ICUI | ▲ Buy | Option Exercise | 485 | $0 | 5/17/2023 | View on chart |
| CE | ▲ Buy | Grant | 1,777 | $175K | 5/12/2023 | View on chart |
| GKOS | ▲ Buy | Grant | 1,572 | $0 | 1/3/2023 | View on chart |
| STEP | ▲ Buy | Grant | 6,053 | — | 9/14/2022 | View on chart |
| GKOS | ▲ Buy | Grant | 4,364 | $0 | 6/2/2022 | View on chart |
| ICUI | ▲ Buy | Option Exercise | 433 | $0 | 5/11/2022 | View on chart |
| CE | ▲ Buy | Grant | 1,098 | $160K | 5/3/2022 | View on chart |
| GKOS | ▲ Buy | Grant | 1,455 | $0 | 1/3/2022 | View on chart |
| STEP | ▲ Buy | Grant | 3,205 | — | 9/24/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
StepStone Partners with ASB, Gets New Analyst Coverage
StepStone Group announced a partnership with ASB Capital Partners to launch a private financing fund and appointed a new vice chairman for Japan. Additionally, Wells Fargo initiated coverage with an overweight rating and a $55 price target. These developments highlight the firm's expansion into new markets and its growing visibility among financial institutions.
StepStone Partners with ASB, Gets New Analyst Coverage. StepStone Group announced a partnership with ASB Capital Partners to launch a private financing fund and appointed a new vice chairman for Japan. Additionally, Wells Fargo initiated coverage with an overweight rating and a $55 price target. These developments highlight the firm's expansion into new markets and its growing visibility among financial institutions.